These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 29057203)

  • 41. The Pursuit of Regulatory T Cells in the Induction of Transplant Tolerance.
    Arnold PR; Li XC
    Adv Exp Med Biol; 2021; 1278():273-287. PubMed ID: 33523453
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Fingerprints of transplant tolerance suggest opportunities for immunosuppression minimization.
    Sarwal MM
    Clin Biochem; 2016 Mar; 49(4-5):404-10. PubMed ID: 26794635
    [TBL] [Abstract][Full Text] [Related]  

  • 43. What can we learn from the transcriptional characterization of spontaneously tolerant transplant recipients?
    Danger R; Racapé M; Soulillou JP; Brouard S
    Curr Opin Organ Transplant; 2010 Aug; 15(4):435-40. PubMed ID: 20616726
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Control and prevention of kidney transplant rejection: the role and possibilities for the clinical use of regulatory T-cells in transplantation].
    Mukhin VE; Polyakova YV; Kaabak MM; Babenko NN; Bryzgalina EV; V'yunkova YN
    Khirurgiia (Mosk); 2019; (9):80-85. PubMed ID: 31532171
    [TBL] [Abstract][Full Text] [Related]  

  • 45. How can we measure immunologic tolerance in humans?
    Najafian N; Albin MJ; Newell KA
    J Am Soc Nephrol; 2006 Oct; 17(10):2652-63. PubMed ID: 16928808
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tolerance-inducing immunosuppressive strategies in clinical transplantation: an overview.
    Golshayan D; Pascual M
    Drugs; 2008; 68(15):2113-30. PubMed ID: 18840003
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dissecting the Multiplicity of Immune Effects of Immunosuppressive Drugs to Better Predict the Risk of
    Cangemi M; Montico B; Faè DA; Steffan A; Dolcetti R
    Front Oncol; 2019; 9():160. PubMed ID: 30972289
    [No Abstract]   [Full Text] [Related]  

  • 48. Cell Therapy as a Tool for Induction of Immunological Tolerance after Liver Transplantation.
    Kholodenko IV; Kholodenko RV; Lupatov AY; Yarygin KN
    Bull Exp Biol Med; 2018 Aug; 165(4):554-563. PubMed ID: 30121913
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neoral use in the cardiac transplant recipient.
    Valantine H
    Transplant Proc; 2000 May; 32(3A Suppl):27S-44S. PubMed ID: 10814748
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Report from the National Transplantation Pregnancy Registry: outcomes of pregnancy after transplantation.
    Armenti VT; Daller JA; Constantinescu S; Silva P; Radomski JS; Moritz MJ; Gaughan WJ; McGrory CH; Coscia LA
    Clin Transpl; 2006; ():57-70. PubMed ID: 18368705
    [TBL] [Abstract][Full Text] [Related]  

  • 51. New approaches to the prevention of organ allograft rejection and tolerance induction.
    Bagley J; Tian C; Iacomini J
    Transplantation; 2007 Jul; 84(1 Suppl):S38-41. PubMed ID: 17632412
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update.
    Staatz CE; Tett SE
    Arch Toxicol; 2014 Jul; 88(7):1351-89. PubMed ID: 24792322
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Minimization of immunosuppression in adult liver transplantation: new strategies and tools.
    Londoño MC; López MC; Sánchez-Fueyo A
    Curr Opin Organ Transplant; 2010 Dec; 15(6):685-90. PubMed ID: 20885324
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunosuppressants in Organ Transplantation.
    Tönshoff B
    Handb Exp Pharmacol; 2020; 261():441-469. PubMed ID: 31820175
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CNS immunological modulation of neural graft rejection and survival.
    Borlongan CV; Stahl CE; Cameron DF; Saporta S; Freeman TB; Cahill DW; Sanberg PR
    Neurol Res; 1996 Aug; 18(4):297-304. PubMed ID: 8875445
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Filtering lymphocytes may decrease the need for immunosuppression in solid organ transplantation.
    Varol U; Toprak O
    Med Hypotheses; 2013 Oct; 81(4):731-3. PubMed ID: 23942029
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Transplant Tolerance Induction: Insights From the Liver.
    Dai H; Zheng Y; Thomson AW; Rogers NM
    Front Immunol; 2020; 11():1044. PubMed ID: 32582167
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Islet transplantation in patients with diabetes mellitus: choice of immunosuppression.
    Nanji SA; Shapiro AM
    BioDrugs; 2004; 18(5):315-28. PubMed ID: 15377174
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunosuppression in Pediatric Heart Transplantation: 2003 and Beyond.
    Reddy SC; Laughlin K; Webber SA
    Curr Treat Options Cardiovasc Med; 2003 Oct; 5(5):417-428. PubMed ID: 12941210
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Daclizumab: a review of its use in the management of organ transplantation.
    Carswell CI; Plosker GL; Wagstaff AJ
    BioDrugs; 2001; 15(11):745-73. PubMed ID: 11707149
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.